Research Article

Current status, complications and prospects of fecal microbiota transplantation therapy

Tadashi Ohara*

Published: 04/15/2021 | Volume 5 - Issue 1 | Pages: 001-009

Abstract

Currently, the emergence of highly virulent mutants in Europe and the United States has caused refractory recurrent Clostridium difficile infection (RCDI) to be a problem in clinical practice. In 2013, the Netherland group demonstrated breakthrough therapeutic efficacy in fecal microbial transplant (FMT) treatment clinical trials for RCDI, and FMT treatment is rapidly gaining attention. In addition to RCDI, FMT treatment has been attempted in various gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome and chronic constipation, as well as extragastrointestinal diseases. In this review, I would like to describe the current status, complications and prospects of FMT treatment.

Read Full Article HTML DOI: 10.29328/journal.apcr.1001021 Cite this Article

References

  1. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013: 368, 407-415. PubMed: https://pubmed.ncbi.nlm.nih.gov/23323867/
  2. Martín R, Bermúdez-Humarán LG, Langella P. Gnotobiotic Rodents, An In Vivo Model for the Study of Microbe-Microbe Interactions. Front Microbiol. 2016; 7; 409. PubMed: https://pubmed.ncbi.nlm.nih.gov/27065973/
  3. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M , Kump P , et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017: 66, 569-580. PubMed: https://pubmed.ncbi.nlm.nih.gov/28087657/
  4. Rook G, Bäckhed F, Levin BR, McFall-Ngai MJ, McLean AR. Evolution, human-microbe interactions, and life history plasticity. Lancet. 2017; 390: 521-530. PubMed: https://pubmed.ncbi.nlm.nih.gov/28792414/
  5. Selber-Hnatiw S, Rukundo B, Ahmadi M, Akoubi H, Al-Bizri H, et al. Toward an Ecology of Disease. Front Microbiol. 2017; 1265.
  6. Carding SR, Davis N, Hoyles L. Review article, the human intestinal virome in health and disease. Aliment Pharmacol Ther. 2017; 46: 800-815. PubMed: https://pubmed.ncbi.nlm.nih.gov/28869283/
  7. Mirzaei MK, Maurice CF. Ménage à trois in the human gut, interactions between host, bacteria and phages. Nat Rev Microbiol. 2017; 15: 397-408. PubMed: https://pubmed.ncbi.nlm.nih.gov/28461690/
  8. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012; 107: 1755. PubMed: https://pubmed.ncbi.nlm.nih.gov/23160295/
  9. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958; 44: 854-859. PubMed: https://pubmed.ncbi.nlm.nih.gov/13592638/
  10. O’Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009; 136: 1913-1924. PubMed: https://pubmed.ncbi.nlm.nih.gov/19457419/
  11. Tang YM, Stone CD. Clostridium difficile infection in inflammatory bowel disease, challenges in diagnosis and treatment. Clin J Gastroenterol. 2017; 10: 112-123. PubMed: https://pubmed.ncbi.nlm.nih.gov/28210836/
  12. Kelly CR, Kunde SS, Khoruts A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol. 2014; 12: 283-288. PubMed: https://pubmed.ncbi.nlm.nih.gov/24107393/
  13. Quraishi MN, Widlak M, Bhala N, Moore D , Price M , et al. Systematic review with meta-analysis, the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017; 46: 479-493. PubMed: https://pubmed.ncbi.nlm.nih.gov/28707337/
  14. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011; 9: 1044-1049. PubMed: https://pubmed.ncbi.nlm.nih.gov/21871249/
  15. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014; 312: 1772-1778. PubMed: https://pubmed.ncbi.nlm.nih.gov/25322359/
  16. Kao D, Roach B, Silva M, Beck P , Rioux K , et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile infection. A Randomized Clinical Trial. JAMA. 2017; 318: 1985-1993. PubMed: https://pubmed.ncbi.nlm.nih.gov/29183074/
  17. Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol. 2016; 51: 1-10. PubMed: https://pubmed.ncbi.nlm.nih.gov/26153514/
  18. Goodrich JK, Waters JL, Poole AC,  Sutter JL, Koren O, et al. Human genetics shape the gut microbiome. Cell. 2014; 159: 789-799. PubMed: https://pubmed.ncbi.nlm.nih.gov/25417156/
  19. Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, et al. Fecal Microbiota Transplantation for Clostridium difficile Infection, A Systematic Review. Ann Intern Med. 2015; 162: 630-638. PubMed: https://pubmed.ncbi.nlm.nih.gov/25938992/
  20. Rossen NG, MacDonald JK, de Vries EM, D’Haens GR, de Vos WM,  Zoetendal EG ,  Ponsioen CY, Fecal microbiota transplantation as novel therapy in gastroenterology, A systematic review. World J Gastroenterol. 2015; 21: 5359-5371. PubMed: https://pubmed.ncbi.nlm.nih.gov/25954111/
  21. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, et al. Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015; 149: 102-109. PubMed: https://pubmed.ncbi.nlm.nih.gov/25857665/
  22. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis, a randomized placebo-controlled trial. Lancet. 2017; 389: 1218-1228. PubMed: https://pubmed.ncbi.nlm.nih.gov/28214091/
  23. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JHA, et al. Findings from a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis. Gastroenterology. 2015; 149: 110-118. PubMed: https://pubmed.ncbi.nlm.nih.gov/25836986/
  24. Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsioen C, et al. Systematic Review and Meta-analysis, Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis. 2017; 23: 1702-1709. PubMed: https://pubmed.ncbi.nlm.nih.gov/28906291/
  25. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis, a randomized placebo-controlled trial. Lancet. 2017; 389: 1218-1228. PubMed: https://pubmed.ncbi.nlm.nih.gov/28214091/
  26. Narula N, Kassam Z, Yuan Y,  Colombel JF, Ponsioen C, et al. Systematic Review and Meta-analysis, Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis. 2017; 23: 1702-1709. PubMed: https://pubmed.ncbi.nlm.nih.gov/28906291/
  27. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, et al. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm Bowel Dis. 2017 23: 116-125. PubMed: https://pubmed.ncbi.nlm.nih.gov/27893543/
  28. Mizuno S, Nanki K, Matsuoka K, Saigusa K, Ono K, et al. Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients. Intest Res. 2017; 15: 68-74. PubMed: https://pubmed.ncbi.nlm.nih.gov/28239315/
  29. Nishida A, Imaeda H, Ohno M, Inatomi O, Bamba S, et al. Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. J Gastroenterol. 2017; 52: 476-482. PubMed: https://pubmed.ncbi.nlm.nih.gov/27730312/
  30. Huang H, Xu H, Luo Q, He J, Li M, et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation, A case report. Medicine. 2019; 98: e16163. PubMed: https://pubmed.ncbi.nlm.nih.gov/31261545/
  31. Zhang X, Tian H, Qiao X, Yang B, Hua Y, et al. Efficacy observation of periodic fecal microbiota transplantation in the treatment of refractory constipation. Zhonghua Wei Chang Wai Ke Za Zhi. 2017; 20: 1355-1359. PubMed: https://pubmed.ncbi.nlm.nih.gov/29280116/
  32. Huang L, Zhu Q, Qu X, Qin H. Microbial treatment in chronic constipation. Science China. Life Sciences. 2018; 61: 744-752. PubMed: https://pubmed.ncbi.nlm.nih.gov/29388040/
  33. Ohara T, Suzutani T. Efficacy of fecal microbiota transplantation in a patient with chronic intractable constipation. Clin Case Rep. 2018; 1-4.
  34. Ohara T. Identification of the microbial diversity after fecal microbiota transplantation therapy for chronic intractable constipation using 16s rRNA amplicon sequencing. Plos One. 14: e0214085. PubMed: https://pubmed.ncbi.nlm.nih.gov/30889205/
  35. Kootte RS, Levin E, Salojärvi J, Smits LP,  Hartstra AV, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017; 26: 611-619.  PubMed: https://pubmed.ncbi.nlm.nih.gov/28978426/
  36. Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143: 913-916.                         PubMed: https://pubmed.ncbi.nlm.nih.gov/22728514/
  37. Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy. A randomized clinical trial. Hepatology. 2017; 66: 1727-1738. PubMed: https://pubmed.ncbi.nlm.nih.gov/28586116/
  38. Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and Reporting Studies Assessing Fecal Microbiota Transplantation, A Systematic Review. Ann Intern Med. 2017; 167: 34-39. PubMed: https://pubmed.ncbi.nlm.nih.gov/28531908/
  39. Cohen NA, Maharshak N. Novel Indications for Fecal Microbial Transplantation, Update and Review of the Literature. Dig Dis Sci. 2017; 62: 1131-1145. PubMed: https://pubmed.ncbi.nlm.nih.gov/28315032/
  40. He Z, Cui BT, Zhang T, Li P, Long CY, et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease , The first report. World J Gastroenterol. 2017; 23: 3565-3568. PubMed: https://pubmed.ncbi.nlm.nih.gov/28596693/
  41. Vujkovic-Cvijin I, Rutishauser RL, Pao M, Hunt PW, Lynch SV, et al. Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes. 2017; 8: 440-450. PubMed: https://pubmed.ncbi.nlm.nih.gov/28541799/
  42. The U.S. Food and Drug Administration (FDA). Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organism. 2019.
  43. Cammarota G, Ianiro G, Gasbarrini A. Faecal microbiota transplantation in clinical practice. Gut. 2017.
  44. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients with Clostridium difficile Infection. Gastroenterology. 2017; 152: 799-811. PubMed: https://pubmed.ncbi.nlm.nih.gov/27866880/
  45. Narayanan SP, Bharucha AE. A Practical Guide to Biofeedback Therapy for Pelvic Floor Disorders. Curr Gastroenterol Rep. 2019; 21: 21. PubMed: https://pubmed.ncbi.nlm.nih.gov/31016468/
  46. Nagai Y. Autonomic biofeedback therapy in epilepsy. Epilepsy Res. 2019; 153: 76-78. PubMed: https://pubmed.ncbi.nlm.nih.gov/30819542/